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Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability 
and the leading monogenic cause of autism spectrum disorder. Although FXS has been 
studied for several decades, there is relatively little basic science or clinical research 
being performed on FXS in China. Indeed, there is a large gap between China and 
Western countries in the FXS field. China has a potentially large number of FXS patients. 
However, many of them are underdiagnosed or even misdiagnosed, and treatments 
are not always administered in the Chinese population. This review discusses the prev-
alence, treatment, and prevention of FXS in China to facilitate an understanding of this 
disease in the Chinese population.
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iNTRODUCTiON
Fragile X syndrome (FXS) is the most significant monogenic cause of intellectual disability (ID) 
and autism spectrum disorder (ASD). FXS is caused by an expansion of CGG repeats >200 in 
the 5′ untranslated region of the fragile X mental retardation 1 gene (FMR1), which is located 
on Xq27.3. The abnormal CGG expansion leads to methylation and transcriptional silencing of 
the FMR1 gene, resulting in a reduction or loss of fragile X mental retardation 1 protein (FMRP). 
FMRP is an mRNA binding protein. FMRP inhibits the translation of numerous genes involved in 
synaptic development and plasticity, which are essential for learning and intellectual development. 
The absence of FMRP causes long, thin, and immature dendritic spines, which lead to deficits in 
cognitive function and learning ability (1). According to the length of CGG repeats, the FMR1 
gene is divided into four types: (1) individuals with 6–44 CGG repeats are normal, and the most 
common sizes are 29 and 30 copies; (2) 45–54 CGG repeats are called “gray zone” or intermediate 
alleles; (3) premutation alleles are in the range of 55–200 CGG repeats; and (4) CGG repeats >200 
are considered full mutations (2).
The full FMR1 mutation is associated with a typical FXS phenotype in males leading to mild to 
severe ID. Eighty-five percent of males with the FXS full mutation have intelligence quotient (IQ) 
scores <70, which is in the ID range. FXS in males is commonly accompanied by physical traits, 
such as macroorchidism, hypotonia, flat feet, soft skin, hyper-flexible joints, and distinct facial 
morphology, including a prominent forehead, long narrow face, and protruding ears (3). However, 
FXS in female individuals tends to be associated with less severe ID in which 30% have an IQ > 85 
and associated behaviors include poor eye contact, anxiety, ASD, compulsive behavior, attention 
deficit hyperactivity disorder (ADHD), and learning disabilities (4).
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Traditionally, it was believed that FMR1 premutation carriers 
were not clinically involved. However, recent data have indi-
cated medical and/or psychiatric problems associated with the 
carrier status. Primarily, the premutation is related to the frag-
ile X-associated primary ovarian insufficiency (FXPOI) and 
fragile X-associated tremor/ataxia syndrome (FXTAS). FXPOI 
is defined as ovarian failure or insufficiency before the age of 
40 years in women with the premutation. Approximately 20% of 
female premutation carriers will have FXPOI. FXTAS is a neu-
rodegenerative disease that is observed in 40% of male and 16% 
of female premutation carriers. FXTAS particularly manifests in 
males >50 years. The core features of FXTAS include intention 
tremor, cerebellar ataxia, polyneuropathy, autonomic dysfunc-
tion, and cognitive decline (5). Additionally, recent studies 
demonstrated a higher prevalence of psychiatric and behavioral 
abnormalities, including hyperactivity, impulsivity, aggression, 
self-injury, social anxiety, and ASD, than in individuals without 
the premutation (6).
Size mosaicism of the CGG repeats has been observed in 
many patients with FXS. In the study by Nolin et al. (7), 38% of 
FXS patients with full mutations and mosaicism have both the 
premutation and full mutation alleles. The IQs of FXS patients 
vary vastly, ranging from normal to severe ID, based on the 
percentage of cells with the full mutation in the mosaicism. The 
probability of size mosaicism is 4/5 FXS patients; thus, the CGG 
size mosaicism is very common among patients with FXS (8).
PRevALeNCe OF THe FMR1 MUTATiON 
iN CHiNA
Fragile X syndrome has been extensively studied around the 
world, especially in Western countries. The general prevalence 
with a full mutation is estimated at 1/4,000 males and 1/5000–
1/8,000 females (9). Since FXS is a typical sex-linked disorder, 
female prevalence is approximately one-half of the male rate. 
Moreover, males exhibit more severe impairments than females 
because females may have one normal X chromosome due to 
the random inactivation of X chromosomes in somatic cells. 
Premutation carriers are very prevalent in the general popula-
tion; the prevalence is approximately 1 in 150–300 females and 
1 in 400–850 males (6). Although FXS affects all ethnic groups, 
the prevalence may vary between populations. Peprah (10) 
showed that the incidence of FXS in countries with significant 
Asian populations, such as Canada, Estonia, Japan, and Taiwan 
was significantly lower than that in Western countries. More 
importantly, the prevalence of FXS in the countries that perform 
routine FMR1 gene screening is higher than in countries that 
do not perform the test. In China, however, there have been few 
FXS-related studies published, due to the lack of awareness of 
FXS and insufficient diagnostic criteria and tools. Therefore, the 
epidemiologic data regarding FXS in China remains unclear.
Several previous studies have reported the prevalence of FXS 
in the Chinese population. Zhong et al. (11) performed a multi-
institutional collaborative study utilizing molecular screening for 
FXS among 1,127 Chinese patients diagnosed with ID; 2.8% of 
patients with ID were screened for the full mutation based on 
the DNA analysis. The prevalence of FXS in China is equivalent 
to the prevalence among Caucasians, which ranges from 2.6 
to 8.7% among individuals with ID. In contrast, another study 
performed an investigation among patients with mild ID in 
Hong Kong. Only 0.6% of 324 patients met the FXS diagnostic 
criteria. According to this result, the prevalence of FXS among 
Chinese individuals with ID is lower than in Western countries 
(12). Tzeng et al. (13) evaluated the mutant rate of the FMR1 gene 
among 10,046 neonatal boys in Taiwan. The premutation and gray 
region mutation rate was 1:1,674 and 1:143, respectively, suggest-
ing that the prevalence of FXS in the Taiwan was lower than in 
Western countries. Chen et  al. (8) estimated the prevalence of 
FXS in mainland China. In the study, Chen et al. recruited 553 
male children between the ages of 6 months and 18 years with 
unknown moderate to severe ID. The FMR1 full mutation was 
present in 0.93% of children with unknown, moderate to severe 
ID. The reported FXS prevalence in this study was also lower 
than in Western countries. These studies indicate that a large-
scale screening program would be worthwhile to determine the 
prevalence of FXS in the Chinese population. However, no large 
epidemiological studies have been conducted to date.
The reason for the different incidence of FXS among the 
Chinese population and Western countries may be due to several 
factors. First, although FXS affects all ethnic groups worldwide, 
the prevalence may vary among different populations because 
of racial differences. Second, different screening methods and 
varying severities of ID among the recruited populations in the 
various available studies may affect the reported prevalence of 
FXS. Additionally, most Chinese pediatricians have limited clini-
cal knowledge of FXS and the associated complex comorbidities, 
which may also affect the assessment of the disease. Very little 
basic and clinical research on FXS occurs in China compared to 
Western countries that lead the world in the FXS research (9). 
Moreover, in younger patients, the typical physical characteristics 
of FXS, such as a long narrow face, protruding ears, and macroor-
chidism, are less obvious (becoming more apparent as the child 
approaches adolescence). This lack of early physical characteris-
tics increases the clinical diagnostic challenge regarding FXS for 
most Chinese pediatricians. To date, confirming an FXS diagnosis 
depends on the detection of FMR1 mutations through molecular 
genetics testing, particularly in younger children. However, not 
many hospitals and institutions can perform genetic testing for 
FMR1 mutations in China. Therefore, many FXS patients may 
have gone undiagnosed due to the reliance on clinical diagnoses, 
particularly in younger children. The low diagnostic rate of FXS 
further results in limited awareness of FXS among the public 
and medical professions and creates a positive feedback loop. 
Additionally, ASD and FXS are not currently included in routine 
medical school training in China. Li et al. (14) performed a study 
on FXS knowledge and attitudes toward FXS among Chinese 
medical college students. Approximately only 30% of these stu-
dents have heard of FXS but are not very familiar with FXS. This 
study highlights the need to increase awareness of FXS in China.
TARGeTeD TReATMeNT FOR FXS
Fragile X mental retardation 1 protein, the translation product of 
FMR1, is a translational regulation factor that can control most 
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of the proteins important for synaptic maturation and plasticity. 
The absence of FMRP results in significant alterations in learning 
and cognition and abnormal synaptic plasticity, including imma-
ture, elongated spines, and enhanced long-term depression (LTD) 
(meaning the weakening of synaptic connections). Overall, the 
degree of FMRP deficiency is positively correlated with the 
severity of FXS and intellectual impairment (15). Furthermore, 
we have gained much understanding regarding the neurobiol-
ogy and mechanisms of FXS from studies of the FMR1 knockout 
(KO) mouse. Based on evidence from the FMR1 KO mouse 
model and early preliminary clinical studies, abnormal synaptic 
plasticity in FXS can be rescued by targeted treatments.
The metabotropic glutamate receptor 5 (mGluR5) pathway is 
one of the pathways dramatically affected by the absence of FMRP. 
The absence or loss of FMRP will lead to enhanced mGluR5 
activity, which results in LTD or abnormal synaptic connections 
(16). Thus, treatment of FXS patients with mGluR5 antagonists 
may improve LTD and the abnormal synaptic plasticity associ-
ated with FXS. FMR1 KO mice models have shown that mGluR5 
antagonists can reverse the social manifestations and behaviors 
of FXS. Thus, the mGluR5 signaling pathway has great signifi-
cance for social interactions. mGluR5 antagonists may serve as 
potential therapeutic drugs to alleviate the behavioral problems 
exhibited by FXS patients (17). In the acute phase, hippocampal 
LTD and protein synthesis can be reversed by treatment with 
mGluR5 antagonists in FMR1 KO mice models. In the chronic 
treatment phase, mGluR5 antagonists can improve cognitive 
ability, auditory hypersensitivity, and abnormal synaptic plastic-
ity. Additionally, mGluR5 antagonists are helpful for treatment of 
macroorchidism. Also, younger children respond better to drug 
intervention than adults (17, 18). These findings have provided 
a basis for the development of mGluR5 antagonists, such as 
mavoglurant (AFQ056), RG7090, and fenobam, to be used in 
human clinical studies.
A multicenter randomized, double-blind study evaluated 
the efficacy and safety of mavoglurant, an mGluR5 antagonist, 
in adolescent patients with FXS. The efficacy of mavoglurant 
was not confirmed in FXS patients (19). Bailey et  al. (3) also 
used these data to show that FXS patients treated with mavo-
glurant did not exhibit a better treatment response than FXS 
patients receiving placebo as measured by the Clinical Global 
Impression-Improvement (CGI-I). Previously, Jacquemont 
et  al. (20) performed a randomized, double-blind, crossover 
study to examine whether AFQ056 could improve the behav-
ioral symptoms of FXS patients. Thirty male patients with FXS 
aged 18–35 years were included. According to the primary out-
come measure, the Aberrant Behavior Checklist-Community 
Edition (ABC-C) score, no significant effects were found at 
day 19 or 20 following AFQ056 treatment. However, when 
an exploratory analysis was performed also measured by the 
ABC-C score, some of the FXS patients who received AFQ056 
treatment exhibited significant improvements compared to 
those receiving placebo. However, the study by Berry-Kravis 
et al. (19) did not show a difference between patients with a full 
mutation and mosaic individuals. Earlier, Berry-Kravis et  al. 
(21) conducted a trial with fenobam, also an mGluR5 antago-
nist, in 12 adults (6 males and 6 females) with FXS. There are 9 
of 12 (5 males and 4 females) FXS patients receiving fenobam 
exhibited improvements in eye contact, social ability, anxiety, 
and motor overactivity compared to those receiving placebo. 
Most importantly, no significant side effects were observed in 
the fenobam treatment group. Particularly, no central nervous 
system adverse events were associated with fenobam treatment. 
The mGluR5 antagonist is relatively safe for individuals with 
FXS. Although mGluR5 antagonists were not significantly help-
ful in most studies of adolescents and adults, a large multicenter 
study using mavoglurant in children 3–6  years old with FXS 
combined with intensive language intervention will take place 
(funded by NeuroNext) in the United States during the next few 
years. It is likely that mavoglurant will be more efficacious in 
young children than older individuals with FXS.
In addition to the mGluR5 pathway, the GABA system is 
another dysfunctional neurotransmitter system in FXS patients. 
GABA is an important inhibitory neurotransmitter in the brain. 
The balance between Glu and GABA is essential for human learn-
ing and memory. Some studies demonstrated that the GABA 
system is downregulated in animal models of FXS. There are 
several GABAergic synapse components that change expression 
in the FMR1 KO mouse model. Additionally, crucial synaptic 
proteins were reduced, including GABAA receptors and enzymes 
involved in GABA production and metabolism. These findings 
have prompted many clinical trials of GABAergic drugs for FXS 
(22, 23). A phase II study of STX209 (arbaclofen), a GABAB 
agonist, was conducted in 63 children and adults with FXS, and 
the Aberrant Behavior Checklist-Irritability subscale was the 
primary outcome measure. No significant difference was detected 
between those receiving STX209 and those receiving placebo. In 
the subsequent exploratory study, STX209 also did not yield a 
better result than placebo in FXS patients. However, the visual 
analog scale (VAS), which was used to rate parent-nominated 
problem behaviors, indicated significant improvement in the 
STX209 group. A post  hoc analysis also revealed a significant 
benefit of STX209 treatment based on the ABC-Social Avoidance 
scale. STX209 was well tolerated, and the most common side 
effects were sedation and headache, which occurred in 8% of 
FXS patients receiving STX209 treatment. Thus, although GABAB 
agonists were not significantly helpful for patients with FXS, they 
may have the potential to improve social function and behavior 
and are well tolerated by patients with FXS (24).
A reduction or loss of FMRP in FXS is also associated with 
the expression of matrix metalloproteinase 9 (MMP9). MMP9 
plays an important role in hippocampal synaptic maturation and 
plasticity. Bilousova et  al. (25) found that hippocampal MMP9 
levels were elevated in the FMR1 KO mouse. The authors also 
evaluated treatment with minocycline, a tetracycline analog, in 
FMR1 KO mice. MMP9 levels were lowered after minocycline 
treatment. Minocycline can improve abnormal synaptic plastic-
ity and improve behavior in FMR1 KO mice. Leigh et  al. (26) 
conducted a controlled trial to confirm the efficacy of minocycline 
in 55 FXS patients ranging from 3.5 to 16 years old. As meas-
ured by the CGI-I, minocycline treatment produced significant 
improvements compared to placebo. Additionally, anxiety and 
mood-related behaviors in the minocycline group were greatly 
reduced compared to those in the control group (VAS scores).
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Additionally, treatment of FXS-related psychiatric and physical 
problems is very important. One important characteristic of 
FXS is the high rate of comorbid seizures, especially in FXS 
patients diagnosed with ASD. The co-occurrence of seizures is 
about 14% in males and 5% in females with full FMR1 mutations. 
Seizures in FXS are more often focal. The high-risk age for onset 
occurs from 4 to 10 years. In addition, these patients, includ-
ing 77% with seizures and 23% without seizures, showed an 
epileptiform abnormality in EEG findings. And they may share 
some benign epilepsy features with centrotemporal spikes. 
A total of 88% (14/16) with seizures are easily to control with one 
or two antiepileptic drugs (27). However, although seizures in 
FXS patients are usually easy to control, they are also associated 
with the overall severity of FXS, particularly regarding the 
comorbidities, which include ASD and anxiety. Seizures impact 
the prognosis and quality of life of patients with FXS. Active 
antiepileptic therapy for FXS and seizures is necessary (28). 
Furthermore, stimulants, selective serotonin reuptake inhibi-
tors, and antipsychotic medications are used for the treatment 
of ASD, anxiety, impulsive behavior, ADHD, or aggressive 
behavior (29). A recent study demonstrated that a low dose of 
sertraline (2.5–5.0 mg/day) for a 6-month period was beneficial 
for overall development, visual reception, and fine motor coor-
dination in young children with FXS aged 2–6 years (30). The 
young children with FXS plus ASD also demonstrated significant 
improvements in expressive language abilities as measured by 
the Mullen Scales of Early Learning (30). These early treatment 
data demonstrate the importance of early diagnosis of FXS so 
that interventions can be started early.
Although most studies have focused on drug treatment for FXS, 
several non-pharmacological interventions can be used to treat 
the condition. Their purpose is to improve behavioral problems 
of FXS patients, such as attention difficulties, social anxiety, poor 
eye contact, stereotypic, or repetitive behaviors. Early intensive 
behavioral interventions are able to stimulate the development of 
social communication and language, joint attention, and daily liv-
ing skills. Applied behavior analysis (ABA), based on functional 
analysis, can be used to find out the environmental factors that 
lead to behavioral problems, and through training to improve the 
behavioral problems of children with FXS (31). Treatment and 
education of autistic and related communication-handicapped 
children, floor time, and relationship development intervention 
are also used to treat behavioral problems of FXS (32). These sup-
portive interventions significantly impact the academic outcome 
and quality of life and are extremely important for the life of 
these children and their families. Another study carried out a 
trial of Cogmed working memory training in FXS. The evidence 
shows that Cogmed training can effectively improve the working 
memory ability of FXS and reduce the symptoms of ADHD (33). 
Therefore, behavioral therapy may have a synergistic effect with 
pharmaceutical targeted treatments that will further improve the 
cognitive ability and behavioral problems of FXS. Importantly, 
the behavioral interventions for autistic like features are becom-
ing more widely used in China.
However, to date, there are no guidelines for the diagnosis and 
management of FXS in China. Moreover, no targeted drug has 
been used to the Chinese market so far. Most of the treatment 
of FXS patients mainly relies on symptomatic treatment of ASD, 
ADHD, or seizures. The biggest obstacle is the limited awareness 
about FXS among medical professionals, the public, and relevant 
departments. Thus, although China has a potentially large num-
ber of FXS patients, basic and clinical trials for FXS patients have 
not been conducted extensively in China. Additionally, there is a 
relatively weak basic and clinical research foundation for FXS in 
China compared with Western countries. Currently, nationwide 
healthcare programs in China cover many basic general health-
care expenses. For example, neonatal screening has developed 
rapidly in recent years, including for phenylketonuria and 
congenital hypothyroidism (34). Furthermore, general screening 
for Down syndrome also has been conducted as part of routine 
prenatal testing in China. However, no national healthcare plans 
cover genetic testing for FXS. Medical insurance does not cover 
the high cost of FXS screening. Thus, many families in under-
developed rural areas cannot afford the cost. This may delay 
treatment for FXS beyond the optimal time. Even after diagnosis, 
behavioral problems in children with FXS often require lifelong 
support, which presents a significant burden for families. Working 
with individuals with FXS will need the combined efforts of the 
family, physicians, and educational system to provide behavioral 
training and other management techniques. The safety and toler-
ability of therapies for FXS patients are also important concerns 
for Chinese families. To conduct treatment for FXS patients in 
China, it is important to obtain the support of the government 
and health-care sectors and attract public attention by provid-
ing information on the importance of active treatment for 
FXS. Population safety and tolerability of treatment modalities 
should also be evaluated. Due to the above reasons, the long-term 
quality of life in FXS is not optimistic in China. A study, which 
evaluate the outcome of Chinese patients with FXS by using social 
adaptive behavior to represent the quality of life, find that the 
adaptive behavior of children with ID is closely related to the 
quality of life. Compared with Down syndrome and typically 
developing boys, boys with FXS had significantly lower scores 
in the work skills, socialization and self-management, after age 
and receptive language ability matched. The findings suggest that 
patients with FXS have much more difficulties in the life living 
than the other two groups. Furthermore, the level of language 
comprehension of Chinese FXS patients was significantly lower 
than that of the patients in western developed countries (35). 
Therefore, there is a long way to go toward the diagnosis and 
treatment of FXS in China.
Recently, an increasing number of clinicians, researchers, and 
the government in China are becoming aware of the significant 
hazards and economic burdens of rare diseases, especially chronic 
diseases. Thus, the prevention and treatment of rare diseases, 
including FXS, has gained increasing attention. We have also 
begun to realize the importance of resource allocation and basic 
and clinical research in China. At the moment, projects on rare 
diseases are being implemented nationwide in China. The pur-
pose of this promotion is to increase the study of rare diseases in 
China and to be in line with the world in the field of FXS (36). 
Although we have begun to improve in the field of FXS, substantial 
gaps still exist between China and Western developed countries. 
Accordingly, we should learn advanced Western technology and 
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research methods to make progress in the testing and treatment 
of FXS. Additionally, coupled with the increased awareness of 
public and government and a significant amount of investment, 
China has the potential to make outstanding contributions to the 
diagnosis and treatment of rare diseases, including FXS.
GeNeTiC COUNSeLiNG TO PReveNT FXS
Although CGG repeats are stable when they are in the normal 
range, they show genetic instability in the gray mutation or 
premutation regions. The premutation frequently expands to the 
full mutation with maternal transmission. As the length of CGG 
repeats increases, the risk of amplification increases. Additionally, 
it is influenced by the number of AGG interruptions. The absence 
of AGG interruptions will lead to more instability of the FMR1 
gene (7). A study showed that more than 94% of FMR1 alleles 
with >90 CGG repeats will expand to full mutations, and 56 CGG 
repeats is the smallest number of repeats that can be extended to 
a full mutation in one generation (7). In general, there are one or 
more AGG interruptions inserted into the CGG repeats. These 
interruptions may influence FMR1 allele stability by stabilizing 
strand slippage during DNA replication. The AGG interruptions 
among the CGG repeats increase the stability of the FMR1 allele 
and decrease the risk of expansion to full mutations during 
maternal transmission. Because of the effect of AGG interrup-
tions on FMR1 allele stability in gray mutation or premutation 
regions, they should be considered when conducting genetic 
counseling (37).
Nolin et  al. (37) evaluated the effect of AGG interruptions 
and CGG repeats on FMR1 allele stability in the gray region and 
found small premutation alleles with 45–69 CGG repeats. Both 
the number of AGG interruptions and the length of CGG repeats 
were associated with allele instability during maternal transmis-
sion. Maternal alleles with no AGG interruptions have the highest 
risk of expansion to full mutation during transmission. All of the 
full mutation expansions in this study were from mothers with 
no AGG interruptions in the CGG repeats. The results suggest 
that the AGG interruptions can reduce the stability of gray region 
and small premutation alleles with 45–69 CGG repeats during 
transmission. Therefore, combined consideration of the number 
of AGG interruptions and the length of CGG repeats during 
genetic counseling will provide a more accurate risk assessment 
of expansion to full mutations. Recently, another study examined 
the stability of maternal and paternal alleles with 45–90 repeats 
during transmission and assessed the effect of AGG interruptions 
on CGG repeat instability. Approximately, half of the full muta-
tion expansions occurred in mothers with no AGG interruptions, 
while 43% of the full mutation expansions occurred with one 
AGG interruptions. Only 4% of full mutation expansions resulted 
from mothers with two AGG interruptions (7).
Although the length of CGG repeats and the number of AGG 
interruptions are significant factors influencing FMR1 allele sta-
bility in the gray region and premutation alleles on transmission, 
other factors, such as maternal age, are likely to have a role when 
considering the risk of expansion to full mutation. Yrigollen et al. 
(38) found that the length of CGG repeats, the number of AGG 
interruptions, and maternal age are the most important factors 
when considering the risk of premutation expansion to full 
mutations during maternal transmission. Interestingly, maternal 
age was related to the risk of expansion to full mutation during 
maternal transmission. The risk of expansion to full mutation 
increases with age. For example, the probability of expansion to 
full mutation is 56% for a 20-year-old mother. However, the risk 
increases to 85% when the mother is aged 30 years. This suggests 
an additive effect of maternal age and allele instability. In addition 
to the effects of the length of the CGG repeat and the number of 
AGG interruptions on stability of FMR1 alleles, maternal age is 
also a significant factor when considering the risk of expansion to 
a full mutation. That is, a younger mother may have a lower risk 
of having expansion to full mutation in a child with CGG repeats. 
However, in the study by Nolin et al. (7), the effect of maternal 
age on the risk of expansion to full mutation revealed only a possi-
ble association with transmission (no significant difference). The 
reason may be that maternal age has less impact on FMR1 allele 
stability than CGG repeats and AGG interruptions when con-
sidering the risk of expansion to full mutation. Therefore, more 
evidence is needed to further demonstrate the effect of maternal 
age on the amplification risk of FMR1 alleles.
The accurate calculated risk rate of expansion to full mutation 
CGG repeats will be an important information for the genetic 
counseling of families with individuals with FXS and premuta-
tion carriers who want to have children. A calculation model that 
includes the length of the CGG repeat, the number of AGG inter-
ruptions, and maternal age is more precise for genetic counseling. 
Women who carry CGG repeats in premutation regions with no 
AGG interruptions have a risk of expansion to full mutation. 
Thus, these women should receive prenatal genetic counseling. 
Although maternal alleles with one or two AGG interruptions 
have lower risks than those with no AGG interruptions, they 
still have a risk of amplification to full mutation according to the 
number of CGG repeats. If a premutation carrier can be iden-
tified in time and the appropriate measures taken, FXS can be 
reduced or prevented in maternal transmission to some degree. 
Broad screening of women during early pregnancy or among those 
who wish to become pregnant is considered a good approach to 
identify carriers with significant risk of expansion to full mutation 
during maternal transmission. However, whether to accept the 
FXS prenatal screening should be a personal decision. Therefore, 
improved public awareness of FXS during early prenatal genetic 
screening can greatly reduce births of FXS children.
Obviously, Down syndrome is familiar to Chinese people. 
However, not everyone recognizes FXS. Although genetic 
counseling has become very advanced in Western countries, 
only a few hospitals and institutions can perform genetic testing 
for FXS in China. The main reason is that the number of CGG 
repeats cannot be evaluated accurately. Molecular diagnostic 
tests for FXS include region-specific CGG PCR amplification 
and Southern blot analysis. Recently, although, some com-
mercial FXS testing trial kits have been introduced in China, 
the high price and technical constraints have hindered wide-
spread use of the kits for genetic testing and prenatal diagnosis. 
Moreover, until now, the cost of genetic testing for FXS has not 
been covered by medical insurance in China as is screening 
for congenital hypothyroidism and phenylketonuria (9). The 
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cost of genetic testing for FXS is a significant family expense, 
especially in underdeveloped areas. Therefore, many of FXS are 
underdiagnosed or misdiagnosed in clinic. At present, there is 
relatively scarce evidence on FXS in China, which is partly due 
to lack of awareness of FXS among doctors, the public, and the 
government. A wide range of actively screening for FXS children 
is rare in China. Unless a highly clinical suspicion, pediatricians 
will think of this condition. It may lead to more and more FXS 
offspring patients in China and will make management and 
treatment more difficult. In addition, treatments are not always 
administered in the Chinese FXS population. Most importantly, 
FXS treatment is a long-term supportive treatment. Once 
diagnosed, further medical treatment will be a substantial 
financial burden for a family. FXS management also brings great 
mental stress to the family and society. Therefore, it is critical to 
consider the basic national condition of China, which is still a 
developing country with lagging economic strength compared 
to developed Western countries. Moreover, China has a very 
large population. The unique characteristics of China require us 
to provide appropriate methods for the diagnosis and treatment 
of FXS. First, we must improve FXS awareness among doctors, 
the public, and the government. Second, special guidelines 
should be created by Chinese language experts to guide doctors 
how best to describe aspects of FXS to patients. Moreover, in the 
current era of network information, we should make full use of 
network resources to introduce basic knowledge of FXS to the 
Chinese public (14).
The prevention and treatment of FXS will be the result of 
comprehensive efforts in various arenas, including government, 
medi cal personnel, and the public. A specialized clinic and 
research center is an urgent necessity in order to provide the latest 
knowledge to Chinese medical professionals. More publicity 
and education are needed to provide information and help to 
individuals with FXS and their families.
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